FibroGen Inc FGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FGEN is a good fit for your portfolio.
News
-
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
-
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
-
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
-
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
-
Thinking about buying stock in Infobird, PubMatic, Hims & Hers Health, FibroGen, or Alpha Metallurgical Resources?
-
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
-
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
-
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- $1.02
- Day Range
- $1.01–1.06
- 52-Week Range
- $0.33–19.46
- Bid/Ask
- $1.04 / $1.05
- Market Cap
- $103.71 Mil
- Volume/Avg
- 290,046 / 2.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.65
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 486
- Website
- https://www.fibrogen.com
Comparables
Valuation
|
Metric
|
FGEN
|
CRNX
|
PMVP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 5.59 | 0.39 |
Price/Sales | 0.65 | 639.90 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
FGEN
CRNX
PMVP
Financial Strength
|
Metric
|
FGEN
|
CRNX
|
PMVP
|
|---|---|---|---|
Quick Ratio | 1.27 | 12.92 | 14.47 |
Current Ratio | 1.52 | 13.07 | 14.78 |
Interest Coverage | −18.14 | — | — |
Quick Ratio
FGEN
CRNX
PMVP
Profitability
|
Metric
|
FGEN
|
CRNX
|
PMVP
|
|---|---|---|---|
Return on Assets (Normalized) | −45.76% | −38.81% | −23.12% |
Return on Equity (Normalized) | — | −44.79% | −25.57% |
Return on Invested Capital (Normalized) | −422.84% | −45.62% | −27.79% |
Return on Assets
FGEN
CRNX
PMVP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kjshxyswsp | Kmpg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wcxzgdpc | Gnxcrw | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xdylfjn | Fddtgb | $97.8 Bil | |
MRNA
| Moderna Inc | Ncbwlkmgk | Gfzpg | $38.8 Bil | |
ARGX
| argenx SE ADR | Mgvmrnfld | Rlrp | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Kvxywbbk | Mpfy | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ybvcgfyk | Psydjf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xpvptrcw | Zcxpgk | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bwfwpzsxls | Mhxngj | $12.5 Bil | |
INCY
| Incyte Corp | Gfcrkkzc | Bpmkr | $11.5 Bil |